Scarica l'app Stockscreener
26.85
6.36%
-1.99
Dopo l'orario di chiusura:
26.70
-0.15
-0.56%
Precedente Chiudi:
$28.84
Aprire:
$29.68
Volume 24 ore:
338.95K
Relative Volume:
4.15
Capitalizzazione di mercato:
$1.19B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-3.93%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$26.32
$29.80
Intervallo di 1 settimana:
$26.01
$29.80
Portata 52W:
$25.05
$32.23
Avalyn Pharma Inc Stock (AVLN) Company Profile
Nome
Avalyn Pharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare AVLN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
26.84 | 1.28B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalyn Pharma Inc Borsa (AVLN) Ultime notizie
This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Evercore Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $51 - Moomoo
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Jefferies Initiates Avalyn Pharma at Buy With $52 Price Target - Moomoo
Morgan Stanley Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $53 - Moomoo
Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating - Investing.com Australia
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs By Investing.com - Investing.com Australia
Jefferies initiates Avalyn Pharma stock with buy on lung disease data - Investing.com
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs - Investing.com Australia
Jefferies Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $52 - Moomoo
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
AVLN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AVLN Technical Analysis | Trend, Signals & Chart Patterns | AVALYN PHARMA INC (NASDAQ:AVLN) - ChartMill
Avalyn Pharma to present 4-year AP01 data at EULAR conference By Investing.com - Investing.com South Africa
Avalyn Pharma to present 4-year AP01 data at EULAR conference - Investing.com
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 - The Manila Times
4 years on inhaled pirfenidone for lung scarring at EULAR 2026 - Stock Titan
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
AVLN SEC FilingsAVALYN PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
AVLN News | AVALYN PHARMA INC (NASDAQ:AVLN) - ChartMill
Number of shareholders of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Avalyn Pharma prices $300M IPO at $18 per share - MSN
Suvretta funds build Avalyn Pharma (AVLN) stake via IPO and open-market buys - Stock Titan
SR One funds disclose 3.31M-share Avalyn Pharma (AVLN) position after IPO - Stock Titan
What is the current Price Target and Forecast for Avalyn Pharma Inc. (AVLN) - Zacks Investment Research
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga
Perceptive group discloses 6.0% stake in Avalyn Pharma (NASDAQ: AVLN) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Avalyn brings patient feedback on lung fibrosis care to ATS 2026 - Stock Titan
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference - The Manila Times
Lung disease drug developer Avalyn surges on public debut - MSN
Novo Holdings (NASDAQ: AVLN) buys shares and converts preferred into Avalyn common - Stock Titan
Avalyn Pharma Insider Bought Shares Worth $5,000,004, According to a Recent SEC Filing - Moomoo
Avalyn Pharma Inc. (AVLN) - Minichart
Preferred dividends of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
After tax other income/expense of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Cash per share of Avalyn Pharma Inc. – BOATS:AVLN - TradingView
Number of employees of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
AVLN PE Ratio & Valuation, Is AVLN Overvalued - Intellectia AI
Avalyn Pharma completes $345 million IPO on nasdaq - Investing.com India
AVLN Price Today: Avalyn Pharma Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Avalyn Pharma completes $345 million IPO on nasdaq By Investing.com - Investing.com Canada
Avalyn Pharma (AVLN) 10K Form and Latest SEC Filings 2026 - MarketBeat
IPO NewsUS IPO Weekly Recap: Biotech, early-stage mining, and Bill Ackman close out the April IPO market - renaissancecapital.com
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs - Citeline News & Insights
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Avalyn Pharma closes $345 million IPO on Nasdaq By Investing.com - Investing.com Australia
Avalyn Pharma Inc. Completes Successful Initial Public Offering Raising $345 Million - Moomoo
Avalyn Pharma Inc Azioni (AVLN) Dati Finanziari
Non sono disponibili dati finanziari per Avalyn Pharma Inc (AVLN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Avalyn Pharma Inc Azioni (AVLN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Carroll Jill | Director |
May 01 '26 |
Buy |
18.00 |
277,778 |
5,000,004 |
2,186,562 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 01 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
2,186,562 |
1.49%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):